Literature DB >> 8491049

Response of vasoactive substances to reduction of blood volume during hemodialysis in hypotensive patients.

B Heintz1, K Reiners, U Gladziwa, R Kirsten, K Nelson, D Wieland, J Riehl, H Mann, H G Sieberth.   

Abstract

Hypotension is a frequent complication in patients subjected to regular hemodialysis. Insufficient regulation of blood pressure following dialysis with ultrafiltration has been attributed to a lack in hormone activation. To determine whether altered production of vasoactive hormones is involved in the breakdown of blood pressure regulation during hemodialysis (HD), blood volume (BV), atrial natriuretic peptide (ANP), plasma renin activity (PRA), aldosterone (Aldo), norepinephrine (NE), epinephrine (Epi), intact immunoreactive parathyroid hormone (iPTH) and arginine vasopressin (AVP) were examined. The relative BV was measured by continuous hemoglobinometry during the HD period of about 240 min. The total decrease in BV at the end of treatment was 23.5 +/- 4.8% of the pretreatment value. Systolic blood pressure (SBP) was 99.6 +/- 23.0 mmHg before dialysis compared with 74.6 +/- 18.8 mmHg at the end of dialysis and heart rate (HR) increased from 76.3 +/- 5.5/min before to 92.0 +/- 10.0/min at the end of dialysis. Despite the wide range of interindividual variance, the hormonal changes indicate that hypotensive patients under HD develop reduced sensitivity of the angiotensin-renin, adrenergic and AVP systems to volumetric stimuli. A paradoxical activation in iPTH and PRA independent Aldo secretions is apparent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491049

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  1 in total

1.  Serum vasopressin response in patients with intradialytic hypotension: a pilot study.

Authors:  Mira Rho; Mark A Perazella; Chirag R Parikh; Aldo J Peixoto; Ursula C Brewster
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.